Clinical features and risk factors of Raynaud’s phenomenon in primary Sjögren’s syndrome
Open Access
- 29 April 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Clinical Rheumatology
- Vol. 40 (10), 4081-4087
- https://doi.org/10.1007/s10067-021-05749-w
Abstract
Objective The aim at the current study was to investigate the clinical characteristics and risk factors of Raynaud’s phenomenon (RP) in patients with primary Sjögren’s syndrome (pSS). Methods Retrospective analysis of the medical records of 333 new-onset pSS patients was performed. Demographic, clinical, and serological data were compared between individuals with and without RP. Logistic regression analysis was used to identify risk factors. Results RP was present in 11.41% of the pSS patients. pSS-RP patients were younger (49.74±14.56 years vs. 54.46±13.20 years, p=0.04) and exhibited higher disease activity (11 [5.75–15] vs. 7 [4–12], p=0.03) than those without. The prevalence of lung involvement was significantly higher in pSS patients with RP (60.53% vs. 17.29%; pp=0.003, p=0.04), anti-RNP positive status (OR=79.41, 95% CI 12.57–501.78; pp=0.002) as prognostic factors for pSS-RP. Conclusion The presence of RP defined a subset of pSS with a unique phenotype, manifesting as increased lung involvement and a higher frequency of anti-RNP antibodies and ACA, as well as greater disease activity. These results suggest that RP has clinical and prognostic value of pSS patients. Further prospective studies with a larger number of subjects are warranted to confirm our findings and assess the prognostic and treatment implications of RP in pSS patients. Key Points • Raynaud’s phenomenon (RP) was present in 38 (11.41%) of 333 patients with primary Sjögren’s syndrome (pSS), with patients with RP exhibiting a younger age and higher disease activity. • The presence of RP indicates a subset of pSS with a unique phenotype, with manifestations including increased lung involvement and a higher frequency of anti-RNP antibodies and anti-centromere antibodies. • Patients with pSS and RP need close follow-up and long-term observation (including assessment of microangiopathy), with specific attention paid to the possible development of clinical features of systemic sclerosis.Funding Information
- the National Nature Science Foundation of China (No. 81801630)
- the National Nature Science Foundation of Hebei Province (No. H2018307047)
This publication has 36 references indexed in Scilit:
- Sjögren's syndrome: Where do we stand, and where shall we go?Journal of Autoimmunity, 2014
- Immunological profiles determine neurological involvement in Sjögren's syndromeEuropean Journal of Internal Medicine, 2014
- Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)Annals Of The Rheumatic Diseases, 2014
- B-cell populations and sub-populations in Sjögren's syndromeLa Presse Médicale, 2012
- EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndromeAnnals Of The Rheumatic Diseases, 2009
- Sjögren's syndromeThe Lancet, 2005
- Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus GroupAnnals Of The Rheumatic Diseases, 2002
- The Association of Estrogen Replacement Therapy and the Raynaud Phenomenon in Postmenopausal WomenAnnals of Internal Medicine, 1998
- RAYNAUD'S PHENOMENON IN PRIMARY SJOGREN'S SYNDROMERheumatology, 1990
- HLA DR alloantigens in different subsets of patients with Sjogren's syndrome and in family members.Annals Of The Rheumatic Diseases, 1983